Clinical Trials of a New Anticancer Drug, 1-Hexylcarbamoyl-5-fluorouracil

1-Hexylcarbamoyl-5-fluororacil (HCFU) is a new anticancer drugdiscovered as a derivative of 5-fluorouracil (5-FU). In thisstudy, peculiar types of toxicity such as a hot sensation, pollakisuriaand urgency to defecate appeared in 23% of the patients, whilegastrointestinal, hematological, hepatic and renal toxicitywas very rarely observed. Blood levels of the HCFU fractionand 5-FU were maintained at high concentrations until four hoursafter administration. In a study of 30 evaluable cases withtumors in the various primary sites, good responses were obtainedin an infant with a recurrence of hepatoblastoma and in a patientwith recurrent cancer of the stomach.